<DOC>
	<DOCNO>NCT02599337</DOCNO>
	<brief_summary>Randomized , open-label , 3-way reference replicate crossover bioequivalence study sorafenib 200 mg tablet nexavar ( reference ) follow 200 mg dose healthy subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Sorafenib Tablet Nexavar</brief_title>
	<detailed_description>This single centre , bioequivalence , open-label , randomize , single-dose , 3-period , 3-sequence , reference replicate , crossover study . 36 healthy adult male non-childbearing potential female , ≥18 ≤65 year age , smoker and/or non-smoker .</detailed_description>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Male nonchildbearing potential female , include postmenopausal female ( absence menses 12 month prior drug administration , bilateral oophorectomy hysterectomy bilateral oophorectomy least 6 month prior drug administration ) surgically sterile female ( hysterectomy tubal ligation least 6 month prior drug administration ) , smoker ( 25 cigarette equivalent daily ) nonsmoker , ≥18 ≤65 year age , BMI &gt; 18.5 &lt; 30.0 kg/m2 body weight ≥50.0 kg male ≥45.0 kg female . 2 . Healthy define : absence clinically significant illness surgery within 4 week prior dose . Subjects vomit within 24 hour predose carefully evaluate upcoming illness/disease . Inclusion predosing discretion Qualified Investigator . absence clinically significant history neurological , endocrinal , cardiovascular , pulmonary , hematological , immunologic , psychiatric , gastrointestinal , renal , hepatic , metabolic disease . lipase within normal laboratory range 3 . Capable consent . 1 . Any clinically significant abnormality abnormal laboratory test result find medical screening positive test hepatitis B , hepatitis C , HIV find medical screening . 2 . Positive urine drug screen screen . 3 . History allergic reaction sorafenib , excipients related drug . 4 . Use drug know induce inhibit CYP3A4 metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , etc . ; examples inhibitor : HIV antiviral , clarithromycin , ciprofloxacin , gestodene , etc . within 30 day prior first study drug administration . 5 . Positive pregnancy test screening . 6 . Any reason , opinion Qualified Investigator , would prevent subject participate study . 7 . Clinically significant electrocardiogram ( ECG ) abnormality ( QTc &gt; 450 ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . 8 . History significant alcohol abuse within one year prior screen regular use alcohol within six month prior screen visit ( fourteen unit alcohol per week [ 1 unit = 150 mL wine , 360 mL beer , 45 mL 40 % alcohol ] ) . 9 . History significant drug abuse within one year prior screen use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] , crack ) within 1 year prior screen . 10 . Participation clinical trial involve administration investigational market drug within 30 day ( 90 day biologics ) prior first dose concomitant participation investigational study involve drug administration . 11 . Use medication topical product without significant systemic absorption : prescription medication within 14 day prior first dosing ; overthecounter product include natural health product ( e.g . food supplement herbal supplement ) within 7 day prior first dosing , exception occasional use acetaminophen ( 2 g daily ) ; depot injection implant drug within 3 month prior first dose . 12 . Donation plasma within 7 day prior dose . Donation loss blood ( exclude volume drawn screen ) 50 mL 499 mL blood within 30 day , 499 mL within 56 day prior first dosing . 13 . Hemoglobin &lt; 128 g/L ( male ) &lt; 115 g/L ( female ) hematocrit &lt; 0.37 L/L ( male ) &lt; 0.32 L/L ( female ) screen . 14 . Breastfeeding subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>bioequivalence</keyword>
</DOC>